Company Description

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States.

The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer’s disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream.

The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.

InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

InMed Pharmaceuticals Inc.

Country	Canada
Founded	1981
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	6
CEO	Eric Adams

Contact Details

Address: 500 West Georgia Street, Suite 1800 Vancouver, BC V6B 0M3 Canada
Phone	604 669 7207
Website	inmedpharma.com

Stock Details

Ticker Symbol	INM
Exchange	NASDAQ
Fiscal Year	July - June
Reporting Currency	USD
CIK Code	1728328
CUSIP Number	457637700
ISIN Number	CA4576377002
SIC Code	2834

Key Executives

Name	Position
Eric A. Adams B.S. Chem., M.I.B.	President, Chief Executive Officer and Director
N. Netta Jagpal	Chief Financial Officer and Corporate Secretary
Michael Woudenberg P.Eng.	Chief Operating Officer
Dr. Eric Chih-Hsien Hsu Ph.D.	Senior Vice President of Preclinical Research and Development
Dr. Sazzad Hossain M.Sc., Ph.D.	Co-Founder
Colin Clancy	Vice President of Investor Relations and Corporate Communications
Jerry P. Griffin	Vice President of Sales and Marketing

Latest SEC Filings

Date	Type	Title
Oct 7, 2026	SCHEDULE 13G/A	Filing
Oct 1, 2026	EFFECT	Notice of Effectiveness
Oct 1, 2026	424B3	Prospectus
Sep 29, 2026	S-4/A	Filing
Sep 18, 2026	8-K	Current Report
Sep 9, 2026	S-4/A	Filing
Sep 9, 2026	425	Filing
Sep 9, 2026	10-K	Annual Report
Aug 14, 2026	SCHEDULE 13G	Filing
Jul 22, 2026	425	Filing

View All SEC Filings